Cargando…

Prominent J Waves and Ventricular Fibrillation Caused by Myocarditis and Pericarditis After BNT162b2 mRNA COVID-19 Vaccination

Detalles Bibliográficos
Autores principales: Uesako, Hayata, Fujikawa, Hirohisa, Hashimoto, Satoshi, Wakabayashi, Tadamasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Canadian Cardiovascular Society. Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830155/
https://www.ncbi.nlm.nih.gov/pubmed/35151782
http://dx.doi.org/10.1016/j.cjca.2022.02.005
_version_ 1784648219338211328
author Uesako, Hayata
Fujikawa, Hirohisa
Hashimoto, Satoshi
Wakabayashi, Tadamasa
author_facet Uesako, Hayata
Fujikawa, Hirohisa
Hashimoto, Satoshi
Wakabayashi, Tadamasa
author_sort Uesako, Hayata
collection PubMed
description
format Online
Article
Text
id pubmed-8830155
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Canadian Cardiovascular Society. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-88301552022-02-11 Prominent J Waves and Ventricular Fibrillation Caused by Myocarditis and Pericarditis After BNT162b2 mRNA COVID-19 Vaccination Uesako, Hayata Fujikawa, Hirohisa Hashimoto, Satoshi Wakabayashi, Tadamasa Can J Cardiol Case Report Canadian Cardiovascular Society. Published by Elsevier Inc. 2022-06 2022-02-10 /pmc/articles/PMC8830155/ /pubmed/35151782 http://dx.doi.org/10.1016/j.cjca.2022.02.005 Text en © 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Uesako, Hayata
Fujikawa, Hirohisa
Hashimoto, Satoshi
Wakabayashi, Tadamasa
Prominent J Waves and Ventricular Fibrillation Caused by Myocarditis and Pericarditis After BNT162b2 mRNA COVID-19 Vaccination
title Prominent J Waves and Ventricular Fibrillation Caused by Myocarditis and Pericarditis After BNT162b2 mRNA COVID-19 Vaccination
title_full Prominent J Waves and Ventricular Fibrillation Caused by Myocarditis and Pericarditis After BNT162b2 mRNA COVID-19 Vaccination
title_fullStr Prominent J Waves and Ventricular Fibrillation Caused by Myocarditis and Pericarditis After BNT162b2 mRNA COVID-19 Vaccination
title_full_unstemmed Prominent J Waves and Ventricular Fibrillation Caused by Myocarditis and Pericarditis After BNT162b2 mRNA COVID-19 Vaccination
title_short Prominent J Waves and Ventricular Fibrillation Caused by Myocarditis and Pericarditis After BNT162b2 mRNA COVID-19 Vaccination
title_sort prominent j waves and ventricular fibrillation caused by myocarditis and pericarditis after bnt162b2 mrna covid-19 vaccination
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830155/
https://www.ncbi.nlm.nih.gov/pubmed/35151782
http://dx.doi.org/10.1016/j.cjca.2022.02.005
work_keys_str_mv AT uesakohayata prominentjwavesandventricularfibrillationcausedbymyocarditisandpericarditisafterbnt162b2mrnacovid19vaccination
AT fujikawahirohisa prominentjwavesandventricularfibrillationcausedbymyocarditisandpericarditisafterbnt162b2mrnacovid19vaccination
AT hashimotosatoshi prominentjwavesandventricularfibrillationcausedbymyocarditisandpericarditisafterbnt162b2mrnacovid19vaccination
AT wakabayashitadamasa prominentjwavesandventricularfibrillationcausedbymyocarditisandpericarditisafterbnt162b2mrnacovid19vaccination